Latest On Harrow Health, Inc (HROW):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-13 00:28 EST | News | Harrow Health falls 23% despite Q1 revenue beat | N/A |  |
| 2023-05-12 10:15 EST | News | Harrow Health, Inc. (HROW) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-11 20:40 EST | News | Harrow Health Non-GAAP EPS of -$0.03, revenue of $26.1M beats by $1.11M | N/A | |
| 2023-04-04 15:38 EST | News | Harrow Health: Buy This Deep Moated Stock Ahead Of Massive Growth | N/A | |
| 2023-03-28 22:50 EST | News | Harrow agrees on $100M secured credit financing with Oaktree Capital | N/A | |
About Harrow Health, Inc (HROW):
Harrow Health, Inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the United States. The company offers ophthalmology based pharmaceutical products; and operates Visionology, an online eye health and medication platform. It also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Its products portfolio includes SURF-201 that is in phase 2 trial for the treatment of post cataract surgery pain and inflammation; SURF-100, which is in phase 2 trial to treat chronic dry eye disease; SURF-200 that is in phase 2 trial for the treatment of episodic dry eye flares; and MELT-100, a d read more...rug candidate, which has completed Phase I clinical trial for procedural sedation. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.
General
- Name Harrow Health, Inc
- Symbol HROW
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 125
- Last Split Factor1:5
- Last Split Date2013-02-08
- Fiscal Year EndDecember
- IPO Date2007-09-28
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.harrowinc.com
Valuation
- Trailing PE 9.64
- Price/Sales (Trailing 12 Mt.) 4.3
- Price/Book (Most Recent Quarter) 7.75
- Enterprise Value Revenue 4.13
- Enterprise Value EBITDA 57.78
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $0.11
- Next Year EPS Estimate $0.23
- Profit Margin -7%
- Operating Margin 2%
- Return on Assets 1%
- Return on Equity -13%
- Revenue 48.87 million
- Earnings Per Share $0.58
- Revenue Per Share $1.89
- Gross Profit 34.41 million
- Quarterly Earnings Growth 15.8%
Highlights
- Market Capitalization 197.73 million
- EBITDA 2.8 million
- Analyst Target Price $14.5
- Book Value Per Share $1.06
Share Statistics
- Shares Outstanding 25.98 million
- Shares Float 19.27 million
- % Held by Insiders 751%
- % Held by Institutions 46.66%
- Shares Short 1.15 million
- Shares Short Prior Month 1.02 million
- Short Ratio 4.62
- Short % of Float 5%
- Short % of Shares Outstanding 4%
Technicals
- Beta 0.89
- 52 Week High $11.1
- 52 Week Low $3.34
- 50 Day Moving Average 8.63
- 200 Day Moving Average 6.78
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Harrow Health, Inc (HROW) Dividend Calendar:
Harrow Health, Inc (HROW) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Harrow Health, Inc (HROW) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Harrow Health, Inc (HROW) Chart:
Harrow Health, Inc (HROW) News:
Below you will find a list of latest news for Harrow Health, Inc (HROW) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Harrow Health, Inc (HROW) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest HROW Trades:
Harrow Health, Inc (HROW) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-09-30 | 8-K (Current report) | |
| 2020-09-30 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-09-30 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-30 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-14 | 8-K (Current report) | |
| 2020-08-10 | 8-K (Current report) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-06 | 8-K (Current report) | |
| 2020-07-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-13 | EFFECT (Notice of Effectiveness) | |
| 2020-07-09 | 8-K (Current report) | |
| 2020-07-09 | CORRESP (Correspondence) | |
| 2020-07-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-08 | UPLOAD (SEC-generated letter) | |
| 2020-07-02 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-07-02 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-06-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-08 | 8-K (Current report) | |
| 2020-06-08 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-08 | 4 (Statement of changes in beneficial ownership of securities) | |
Harrow Health, Inc (HROW) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Harrow Health, Inc (HROW). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 751%
Institutional Ownership: 4666%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-28 | Principi Anthony | Director | Buy | 93,798.00 | 93,798.00 | | ||
| 2020-07-12 | Opaleye Management Inc. | 10% Share Holder | Buy | 1,900.00 | 4.98 | 9,462.19 | 131,900.00 | |
| 2020-07-12 | Opaleye Management Inc. | 10% Share Holder | Buy | 19,000.00 | 4.99 | 94,783.40 | 2,827,100.00 | |
| 2020-07-11 | Opaleye Management Inc. | 10% Share Holder | Buy | 46,800.00 | 4.96 | 231,922.08 | 2,808,100.00 | |
| 2020-07-10 | Opaleye Management Inc. | 10% Share Holder | Buy | 45,000.00 | 4.98 | 223,965.00 | 2,761,300.00 | |
| 2020-07-09 | Opaleye Management Inc. | 10% Share Holder | Buy | 5,000.00 | 4.82 | 24,078.50 | 130,000.00 | |
| 2020-07-09 | Opaleye Management Inc. | 10% Share Holder | Buy | 25,000.00 | 4.84 | 121,000.00 | 2,716,300.00 | |
| 2020-07-08 | Opaleye Management Inc. | 10% Share Holder | Buy | 65,000.00 | 4.99 | 324,629.50 | 2,691,300.00 | |
| 2020-07-07 | Opaleye Management Inc. | 10% Share Holder | Buy | 41,300.00 | 5.18 | 213,995.95 | 2,626,300.00 | |
| 2020-06-19 | Opaleye Management Inc. | 10% Share Holder | Buy | 35,000.00 | 5.58 | 195,401.50 | 2,585,000.00 | |
| 2020-06-04 | Opaleye Management Inc. | 10% Share Holder | Buy | 10,000.00 | 5.79 | 57,861.00 | 2,550,000.00 | |
| 2020-06-03 | Opaleye Management Inc. | 10% Share Holder | Buy | 20,600.00 | 5.74 | 118,307.86 | 2,540,000.00 | |
| 2020-06-02 | Opaleye Management Inc. | 10% Share Holder | Buy | 19,400.00 | 5.69 | 110,339.44 | 2,519,400.00 | |
| 2020-05-22 | Opaleye Management Inc. | 10% Share Holder | Buy | 5,000.00 | 5.02 | 25,105.00 | 125,000.00 | |
| 2020-05-22 | Opaleye Management Inc. | 10% Share Holder | Buy | 8,804.00 | 5.05 | 44,483.97 | 2,500,000.00 | |
| 2020-05-21 | Opaleye Management Inc. | 10% Share Holder | Buy | 200.00 | 4.70 | 939.62 | 120,000.00 | |
| 2020-05-21 | Opaleye Management Inc. | 10% Share Holder | Buy | 10,396.00 | 4.66 | 48,398.58 | 2,491,196.00 | |
| 2020-05-20 | Opaleye Management Inc. | 10% Share Holder | Buy | 1,200.00 | 4.50 | 5,397.72 | 119,800.00 | |
| 2020-05-20 | Opaleye Management Inc. | 10% Share Holder | Buy | 300.00 | 4.47 | 1,341.00 | 2,480,800.00 | |
| 2020-03-16 | STEPHEN G AUSTIN | Director | Buy | 72,218.00 | 91,987.00 | |